You are here

  • Home
  • Archive
  • Volume 75, Issue 11
  • Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

Share

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

Share this article

Click the icon of the social media platform on which you would like to share this article.

Twitter logo Facebook logo LinkedIn logo

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
Enter multiple addresses on separate lines or separate them with commas.
Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study
(Your Name) has forwarded a page to you from Annals of the Rheumatic Diseases
(Your Name) thought you would like to see this page from the Annals of the Rheumatic Diseases web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.